Virbac SA (VIRB)

Currency in EUR
354.50
+4.00(+1.14%)
Closed·
VIRB is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
350.50355.50
52 wk Range
249.70371.50
Key Statistics
Prev. Close
354.5
Open
352
Day's Range
350.5-355.5
52 wk Range
249.7-371.5
Volume
3.05K
Average Volume (3m)
4.04K
1-Year Change
13.99%
Book Value / Share
127.18
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
VIRB Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
403.20
Upside
+13.74%
Members' Sentiments
Bearish
Bullish
ProTips
Cash flows can sufficiently cover interest payments

Virbac SA News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy

Virbac Company Profile

Virbac SA manufactures and sells a range of products and services for companion and farm animals in Europe, North America, Latin America, East Asia, India, Africa, the Middle East, and the Pacific. The company offers a range of vaccines, antibiotics, parasiticides, and anti-inflammatory drugs, as well as dermatology, dental, specialty, diagnosis, nutrition, petfood, and pharmaceutical products. It serves veterinarians, farmers, and pet owners. The company was founded in 1968 and is headquartered in Carros, France.

Employees
6365
Market
France

Compare VIRB to Peers and Sector

Metrics to compare
VIRB
Peers
Sector
Relationship
P/E Ratio
22.3x27.3x−0.6x
PEG Ratio
−4.020.000.00
Price/Book
2.8x2.3x2.6x
Price / LTM Sales
2.1x3.1x3.2x
Upside (Analyst Target)
15.3%8.9%41.8%
Fair Value Upside
Unlock10.6%5.1%Unlock

Analyst Ratings

7 Buy
2 Hold
0 Sell
Ratings:
9 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 403.20
(+13.74% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Kepler Cheuvreux
Buy415.00+17.07%390.00Upgrade31/10/2025
Jefferies
Hold368.00+3.81%333.00Maintain22/10/2025
Jefferies
Hold333.00-6.06%346.00Maintain18/09/2025
Stifel
Buy390.00+10.01%380.00Upgrade17/03/2025

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 15.88%
Dividend Yield
0.41%
Industry Median 4.24%
Annualised payout
1.45
Paid annually
5-Years Growth
-
Growth Streak

Earnings

Latest Release
Oct 16, 2025
EPS / Forecast
-- / --
Revenue / Forecast
364.00M / 349.30M
EPS Revisions
Last 90 days

Virbac (VIRB) Income Statement & Profits

People Also Watch

46.90
EXENS
-0.32%
22.85
CBLP
+0.88%
80.90
MWDP
-0.43%
8.16
TFFP
-0.12%

FAQ

What Is the Virbac (VIRB) Share Price Today?

The live Virbac share price today is 354.50

What Stock Exchange Does Virbac (VIRB) Trade On?

Virbac is listed and trades on the Paris Stock Exchange.

What Is the Ticker (Stock Symbol) for Virbac?

The stock symbol (also called a 'ticker') for Virbac is "VIRB."

Does Virbac Pay Dividends? What’s The Current VIRB Dividend Yield?

Yes, VIRB Pays Dividends to its Shareholders. The current Virbac dividend yield is 0.41%.

What Is the Current Virbac Market Cap?

As of today, Virbac market capitalisation is 2.97B.

What Is Virbac's (VIRB) Earnings Per Share (TTM)?

The Virbac EPS is currently 15.88 (Trailing Twelve Months).

When Is the Next Virbac Earnings Date?

Virbac's next earnings report will be released on 24 Mar 2026.

Is VIRB a Buy or Sell From a Technical Analyst Perspective?

Based on today's Virbac moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Virbac Stock Split?

Virbac has split 2 times. (See the VIRB stock split history page for full effective split date and price information.)

How Many Employees Does Virbac Have?

Virbac has 6365 employees.

What is the current trading status of Virbac (VIRB)?

As of 24 Dec 2025, Virbac (VIRB) is trading at a price of 354.50, with a previous close of 354.50. The stock has fluctuated within a day range of 350.50 to 355.50, while its 52-week range spans from 249.70 to 371.50.

What Is Virbac (VIRB) Price Target According to Analysts?

The average 12-month price target for Virbac is EUR403.2, with a high estimate of EUR420 and a low estimate of EUR368. 7 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +13.74% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.